A new study suggests that a minimally invasive, image-guided treatment for uterine fibroids is used a lot less than other surgical treatments. Hysterectomies were performed 65 times more than the minimally invasive uterine fibroid embolization (UFE), which has even been proven to cost less and result in a shorter hospital stay. “These findings suggest there […]
Women's Health
Glenmark, Evestra ink deal to develop generic NuvaRing
Glenmark Pharmaceuticals and Evestra said today that the companies inked a development, license and commercialization deal for a generic version of Merck’s NuvaRing. Development of the etonogestrel/ethinyl estradiol contraceptive is under way, according to the companies, and they plan to file an Abbreviated New Drug Application in fiscal 2019. “This is an important U.S.-based strategic partnership […]
FDA accepts Allergan’s new drug application for Liletta contraception device
Allergan (NYSE:AGN) and the global nonprofit women’s health company Medicines360 said today that the FDA accepted its supplemental New Drug Application for the Liletta contraception device. The companies are asking the federal watchdog to extend the system’s duration of use from 3 years to 4 years. Liletta is a levonorgestrel-releasing intrauterine system that is placed […]
Researchers show drug, catheter combo speeds up labor delivery
Using the drug misoprostol in combination with a Foley balloon catheter to induce labor can lead to a speedier delivery, with women delivering several hours earlier than either method alone, according to research from the University of Pennsylvania. The team’s work was published in Obstetrics & Gynecology. Nearly 1 million women who deliver in the U.S. […]
Immunovaccine’s targeted ovarian cancer therapy wins orphan drug status in EU
Immunovaccine Inc. said today that the European Medicines Agency granted orphan drug designation for its immunotherapy candidate for ovarian cancer in the EU. Orphan drug designation is granted to medicines intended for disease with a prevalence no greater than 5 in 10,000 people. According to the Nova Scotia-based company, ovarian cancer affects 3 per 10,000 […]
Researchers stunt growth of ovarian cancer with nanohydrogels
Researchers at the Georgia Institute of Technology have developed a targeted therapy using nanohydrogels to stunt the growth of ovarian tumors in in vivo tests in mice, according to a new study. The nanohydrogel is a gel pellet that researchers can load with RNA to carry into cancer cells and knock down a particular protein. “The dramatic […]
CERN researcher’s fertility app is as good as oral contraceptives, condoms
Natural Cycles, the fertility app developed by former CERN particle physicist Elina Berglund, is reportedly as effective at preventing pregnancy as oral contraceptives or condoms, boasting a 99.5% efficacy rate. Berglund began working on the app while she was still at the particle physics laboratory in Geneva, she told Wired. “I wanted to give my […]
FDA approves Bayer’s Kyleena IUD
Bayer (ETR:BAYN) said yesterday that it won FDA approval for its hormonal contraceptive device, Kyleena, to prevent pregnancy for up to 5 years. The German company said the long-acting reversible contraceptive (LARC) is due to hit the market next month. LARCs are an increasingly popular form of birth control, including intrauterine devices like Kyleena. Bayer’s […]
